Helene Gauthier
Overview
Explore the profile of Helene Gauthier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gabriel P, Gauthier H, Xylinas E, Hermieu J, Desgrandchamps F, Hennequin C, et al.
Clin Genitourin Cancer
. 2025 Mar;
23(2):102312.
PMID: 40023937
Purpose: Emerging therapies including anti-PD-(L)1 immunotherapy have changed paradigms of treatment and improved oncological outcomes of advanced/metastatic urothelial carcinoma (mUC) patients. An emerging challenge in this setting is the management...
2.
Houede N, Chevallier T, Audenet F, Thibault C, Neuzillet Y, Abraham C, et al.
J Clin Oncol
. 2025 Feb;
:JCO2500179.
PMID: 39951246
Purpose: After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin +...
3.
Dumont C, Aregui A, Hauchecorne M, Lefevre M, Aussedat Q, Reignier P, et al.
World J Urol
. 2023 Aug;
41(10):2715-2722.
PMID: 37555987
Purpose: This study aimed at describing the feasibility and oncological outcomes of standard cisplatin-based neoadjuvant chemotherapy (C-NAC) for muscle-invasive bladder cancer (MIBC) in patients aged ≥ 75 and assess the...
4.
Reignier P, Gauthier H, Hennequin C, Aussedat Q, Xylinas E, Desgrandchamps F, et al.
World J Urol
. 2023 Jul;
41(11):3249-3255.
PMID: 37410102
Purpose: to assess the respective outcomes of patients with localized muscle-invasive bladder cancer (MIBC) treated by either radical cystectomy (RC) or trimodal treatment (TMT) depending on pathological response to previous...
5.
Plais H, Dumont C, Gauthier H, Culine S
Immunotherapy
. 2023 May;
15(10):729-735.
PMID: 37139988
The optimal duration of treatment for metastatic patients who achieve a complete response with immune checkpoint inhibitors is unknown. The outcome for six metastatic bladder cancer patients who received short...
6.
Helal C, Lambert T, Joly B, Dumont C, Gauthier H, Culine S
Case Rep Oncol
. 2022 Sep;
15(2):745-749.
PMID: 36157695
Heart metastases from urothelial carcinoma of the bladder have rarely been reported in the literature. We present a case complicated by symptomatic disseminated intravascular coagulation in a 67-year-old woman. A...
7.
Benzidia I, Crichi B, Montlahuc C, Rafii H, NDour A, Sebuhyan M, et al.
J Thromb Thrombolysis
. 2021 Jul;
53(2):417-424.
PMID: 34296382
Introduction: Treatment of Venous thromboembolism (VTE) in cancer patients is challenging due to higher risk of VTE recurrence or bleeding under anticoagulants. We assessed the effectiveness of a dedicated "Allo-Thrombosis...
8.
Ferris R, Spanos W, Leidner R, Goncalves A, Martens U, Kyi C, et al.
J Immunother Cancer
. 2021 Jun;
9(6).
PMID: 34083421
Background: Head and neck squamous cell carcinomas (HNSCCs) are common malignancies caused by carcinogens, including tobacco and alcohol, or infection with human papillomavirus (HPV). Immune checkpoint inhibitors targeting the programmed...
9.
Daoudi H, Labeyrie M, Guillerm S, Delanian S, Guichard J, Jourdaine C, et al.
Laryngoscope Investig Otolaryngol
. 2020 Mar;
5(1):19-23.
PMID: 32128426
Objective: Osteoradionecrosis (ORN) of the sphenoid is a rare but potentially lethal complication that can occur after irradiation of nasopharyngeal and clival malignancies. The objective of this study was to...
10.
Sroussi M, Elaidi R, Flechon A, Lorcet M, Borchiellini D, Tardy M, et al.
Clin Genitourin Cancer
. 2019 Dec;
18(4):295-303.e3.
PMID: 31882335
Background: Neuroendocrine carcinoma of the urinary bladder (NCUB) is rare, accounting for < 1% of bladder cancer cases, with scarce reported data available. Materials And Methods: We retrospectively reviewed the...